AASS

Across TCGA pan-cancer cohorts, AASS Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated AASS data layer compared with 22 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher AASS Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated AASS expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, ACC, and KIRC are the cancer types where AASS Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.121	0.542	<.001	42	view →
ACC	OS	Median	All	0.273	0.802	.017	15	view →
KIRC	OS	Median	All	0.244	0.805	.028	12	view →
LUAD	OS	Median	II,III,IV	0.004	0.751	<.001	12	view →
UCEC	OS	Median	All	0.908	0.649	.034	8	view →
LIHC	OS	Median	II,III,IV	0.239	0.715	.035	3	view →
BLCA	DFS	Median	IV	0.122	0.475	.025	3	view →
COAD	DFS	Median	III,IV	0.263	0.669	.026	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

AASS–OV (DFS)

Open the OV breakdown →